CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended		184 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Revenues:
Grant revenue		$ 200,400	$ 12,963,100
Collaboration revenue			2,283,600
Other			1,123,500
Total revenues		200,400	16,370,200
Operating expenses:
Research and development	2,480,600	3,430,800	32,036,300
Acquired in-process research and development			7,523,200
General and administrative	2,548,300	3,562,700	33,229,400
Total operating expenses	5,028,900	6,993,500	72,788,900
Loss from operations	(5,028,900)	(6,793,100)	(56,418,700)
Other expenses, net:
Interest expense, net	(1,503,000)	(920,700)	(11,865,200)
Change in warrant and put and note extension option liabilities	3,566,900	(1,635,800)	2,349,600
Loss on early extinguishment of debt		(3,567,800)	(4,761,300)
Other income		34,400	81,900
Loss before income taxes	(2,965,000)	(12,883,000)	(70,613,700)
Income taxes	(2,700)	(3,700)	(23,200)
Net loss	(2,967,700)	(12,886,700)	(70,636,900)
Deemed dividend on Series A Preferred stock		(10,193,200)	(10,193,200)
Net loss attributable to common stockholders	(2,967,700)	(23,079,900)	(80,830,100)
Basic net loss attributable to common stockholders per common share	$ (0.14)	$ (1.27)
Diluted net loss attributable to common stockholders per common share	$ (0.19)	$ (1.27)
Weighted average shares used in computing basic net loss attributable to common stockholders per common share	21,973,149	18,108,444
Weighted average shares used in computing diluted net loss attributable to common stockholders per common share	21,973,149	18,108,444
Comprehensive loss	$ (2,967,700)	$ (12,886,700)	$ (70,636,900)